Waters to Create Laboratory in China for Pharmacopoeia Standards | GenomeWeb

NEW YORK (GenomeWeb) – Waters today announced that it will establish a joint open laboratory with the Chinese Pharmacopoeia Commission.

The lab, which will be located in the Beijing Zhendong Guangming Drug Research Institute, is slated to open by the end of the year. Activities there will be directed at research into pharmacopoeia standards, developing testing methods, validating the methods, and providing training in pharmacopoeia detection methods. The lab, the partners said, is anticipated to become a national technical support center in Chinese pharmaceutical standards.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: global genetic diversity map, and more.

The Nuffield Council on Bioethics identifies ethical questions to explore surrounding genome editing.

In a blog post, Brigham and Women's Hospital's Robert Green discusses "predispositional personal genome sequencing."

Stat News reports that there's muted opposition to the Kuwaiti DNA database law.